|
1)Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Res. 2011; 13: 163-72
|
|
|
|
|
2）Sechi LA, Colussi G, Di Fabio A, et al. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens. 2010; 23: 1253-60
|
|
|
|
|
3）Dluhy RG, Williams GH. Aldosterone-villain or bystander? N Engl J Med. 2004; 351: 8-10
|
|
|
|
|
|
4）Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrien Society 2009. Endocr J. 2011; 58: 711-21
|
|
|
|
|
5）日本高血圧学会高血圧治療ガイドライン作成委員会．高血圧治療ガイドライン2009．日本高血圧学会．2009．p.102-4
|
|
|
|
|
|
6）Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93: 3266-81
|
|
|
|
|
|
7）Sartori M, Calo LA, Mascagna V, et al. Aldoster-one and refractory hypertension: a prospective cohort study. Am J Hypertens. 2006; 19: 373-9
|
|
|
|
|
|
8）Pitt B, Zannad F, Remmer WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-17
|
|
|
|
|
|
9）Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21
|
|
|
|
|
|
10）Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21
|
|
|
|
|
|
11）Goodfriend TL, Ball DL, Raff H, et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004; 43: 358-63
|
|
|
|
|
|
12）Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003; 100: 14211-6
|
|
|
|
|
|
13）Zennaro MC, Caprio M, Feve B. Mineralo-corticoid receptors in the metabolic syndrome. Trends Endocrinol Metab. 2009; 20: 444-51
|
|
|
|
|
|
14）Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009; 150: 776-83
|
|
|
|
|
|
15）Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syn-drome. Curr Hypertens Rep. 2010; 12: 252-7
|
|
|
|
|
|
16）Somloova Z, Widimsky J Jr, Rosa J, et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J Hum Hypertens. 2010; 24: 625-30
|
|
|
|
|
|
17）Shibata H, Itoh H. Mineralocorticoid receptor-associated hyeprtension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012; 25: 514-23
|
|
|
|
|
|
18）Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2012; 26: 281-7
|
|
|
|
|
|
19）Gaddam K, Pimenta E, Thomas SJ, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010; 24: 532-7
|
|
|
|
|
|
20）Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertensoin. 2011; 57: 1076-80
|
|
|
|
|
|
21）柴田洋孝，伊藤 裕．鉱質コルチコイド受容体の転写とエピジェネティクス．最新医学．2010; 65: 79-87
|
|
|
|
|
|
22）Bertocchio JP, Warnock DG, Jaisser F. Mineralo-corticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011; 79: 1051-60
|
|
|
|
|
|
23）Oyamada N, Sone M, Miyashita K, et al. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinol-ogy. 2008; 149: 3764-77
|
|
|
|
|
|
24）Guo C, Martinez-Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006; 147: 5363-73
|
|
|
|
|
|
25）Quinkler M, Zehnder D, Eardley KS, et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005; 112: 1435-43
|
|
|
|
|
|
26）Yokota K, Shibata H, Kurihara I, et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem. 2007; 282: 1998-2010
|
|
|
|
|
|
27）Kino T, Jaffe H, Amin ND, et al. Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotro-phic factor. Mol Endocrinol. 2010; 24: 941-52
|
|
|
|
|
|
28）Viengchareun S, Kamenicky P, Teixeira M, et al. Osmotic stress regulates mineralocorticoid receptor expression in a novel aldosterone-sensitive cortical collecting duct cell line. Mol Endocrinol. 2009; 23: 1948-62
|
|
|
|
|
|
29）Shibata S, Nagase M, Yoshida S, et al. Modifi-cation of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008; 14: 1370-6
|
|
|
|
|
|
30）Shibata S, Mu SY, Kawarazaki H, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011; 121: 3233-43
|
|
|
|
|
|
31）Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hyper-tension exacerbated by pregnancy. Science. 2000; 289: 119-23
|
|
|
|
|
|
32）Hultman ML, Krasnoperova NV, Li S, et al. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol. 2005; 19: 1460-73
|
|
|
|
|